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Anti-cancerHepatocellular carcinoma (HCC) is an invasive cancer with a high rate of recurrence andmetastasis. Agents with
anti-proliferative as well as anti-metastatic activity will be ideal for effective treatment. Here, we demonstrated
that berberine, an isoquinoline alkaloid, harbored potent anti-metastatic and anti-proliferative activities in vivo.
Using an orthotopicmodel of HCC (MHCC-97L), which spontaneously develops lungmetastases (one of themost
common sites of HCC metastasis), we found that berberine treatment (10 mg/kg/2 days) signiﬁcantly reduced
lung metastasis from the liver tumors by ~85% (quantitated by bioluminescence emitted from lung metastases).
Histological examination also conﬁrmed the reduced incidence and number of lung metastases in berberine-
treated mice. Furthermore, berberine effectively suppressed extra-tumor invasion of the primary HCC implant
into the surrounding normal liver tissue, illustrating its potent anti-metastatic action in vivo. Consistentwith pre-
vious reports in other cancer, berberine's anti-tumor activity was accompanied by suppression of cellular prolif-
eration, invasiveness and HIF-1α/VEGF signaling. Strikingly, further mechanistic investigation revealed that
berberine exerted profound inhibitory effect on the expression of Id-1, which is a key regulator for HCC develop-
ment andmetastasis. Berberine could suppress the transcription level of Id-1 through inhibiting its promotor ac-
tivity. Speciﬁc downregulation of Id-1 by knocking down its RNA transcripts in HCC cells inhibited cellular
growth, invasion and VEGF secretion, demonstrating the functional relevance of Id-1 downregulation induced
by berberine. Lastly, berberine's anti-proliferative and anti-invasive activities could be partially rescued by Id-1
overexpression in HCC models, revealing a novel anti-cancer/anti-invasive mechanism of berberine via Id-1
suppression.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Berberine is a quaternary ammonium salt from the group of
isoquinoline alkaloids [1]. It is believed to be the major anti-tumor in-
gredient of a traditional Chinese medical herb, Coptis Rhizome [2]. Coptis
Rhizome has been used for centuries by Chinese medicine physician for
the treatment of cancer and inﬂammatory diseases [2]. Berberine is
known to possess potent anti-cancer activity in several cancer models
including, breast, gastric and colon cancers, nasopharyngeal carcinoma
(NPC) as well as HCC [3–8]. The anti-tumor activity of berberineatomy, Li Ka Shing Faculty of
ry Block, Faculty of Medicine
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yfeng@hku.hk (Y. Feng).includes the induction of cancer cell apoptosis through affecting the
normal mitochondria functioning [5,8], anti-angiogenesis by de-
stabilizing of HIF-1α protein in hypoxic gastric adenocarinoma cells
[7], and suppressing of VEGF secretion in breast and gastric cancer
cells [6,7]. Our recent studies of berberine's anti-cancer action also re-
vealed that it can inhibit STAT3 activation which is signaled by tumor-
associated ﬁbroblasts [9] and inactivate RhoGTPases to interrupt cyto-
skeletal dynamics and cell mobility in NPC [3]. Studies showed that ber-
berine, a pure compound originally derived from plants, has good safety
proﬁle withminimal toxicity [10]. Thus, further development of berber-
ine for metastatic cancer prevention and treatment will be beneﬁcial.
Hepatocellular carcinoma (HCC) is a common malignancy world-
wide with an annual incidence of N780,000 new cases/year. Especially
in Asian countries, it is the leading cause of cancer deaths [11–13].
HCC is a highly invasive and metastatic cancer, which is characterized
by active growth, neovascularization andmetastasis [14,15]. Recurrence
and metastasis are the major causes of HCC deaths [12,14]. Therefore,
agents with good antitumor activity as well as anti-metastatic activity
542 C.M. Tsang et al. / Biochimica et Biophysica Acta 1852 (2015) 541–551would be ideal for HCC treatment. On the other hand, it is of great inter-
est to understand the mechanism behind the anti-cancer and anti-
metastatic effects of berberine in the context of HCC. Previously our
group published that the proliferation, angiogenesis and metastasis of
HCC correlated with the expression of Id-1 (Inhibitor of differentia-
tion/DNA binding) [16]. It is a helix–loop–helix protein expressed in
highly proliferating cells [17]. It lacks the basic domain necessary for
DNAbinding, and therefore acts primarily as dominant-negative regula-
torswhen forming heterodimers with other bHLH proteinswhich inﬂu-
ences downstream events [18]. Overexpression of Id-1 promotes
tumorigenicity and cancer progression inmore than 20 types of cancers
[18–22]. We have reported that ectopic expression of Id-1 could en-
hance cell proliferation and survival in prostate cancer, gastric cancer
and NPC through modulating various signaling pathways including
PI3K, Raf/MEK and NF-kappaB [19–21]. Apart from its oncogenic func-
tion, recent studies have demonstrated that Id-1 is involved in malig-
nant progression of human cancers. In esophageal cancer, we have
reported that Id-1 promoted metastasis by modulating PI3K/Akt-
dependent expression ofmatrixmetalloproteinase (MMP)-9 [22]. In ad-
dition, high level of Id-1 expressionwas associatedwith tumor invasion
and disease progression of breast cancers in in vivomodels [23]. Knock-
down of Id-1 signiﬁcantly suppressed the secretion of MMPs and cancer
metastasis in xenograft models [23]. Angiogenesis is another crucial
step in cancer progression, which provides adequate oxygen and nutri-
ent supply for the continuous expansion of the primary tumor and the
development of metastasis. We and others have provided evidence in
supporting the role of Id-1 in inducing angiogenesis [16,24,25]. For ex-
ample, Id-1 regulated angiogenesis through transcriptional activation
of VEGF by stabilizing HIF-1α protein in HCC [16]. Studies on Id-1
knockout mice also revealed that Id-1 expression was required for
tumor-associated angiogenesis and cancer progression [24]. Taken to-
gether, Id-1 is a versatile protein which takes important roles in
governing tumorigenic and invasive properties of cancer cells. Inactiva-
tion of Id-1 may have potential therapeutic value against primary and
metastatic growth of HCC.
In this study, we investigated the in vivo anti-tumor as well as the
anti-metastatic activities of berberine. Lung is the most common site
of metastases for HCC. Here, we established a spontaneous metastasis
model of HCC (developed from HCC xenograft implants in the liver) in
nude mice. Using bioluminescence imaging, we found that berberine
treatment could signiﬁcantly reduce lung metastasis from the liver im-
plant, as evident by reduced incidence and number of lung metastases.
This was coupled with reduction of invasive margins from the primary
HCC implant into the surrounding normal liver tissue. Further mecha-
nistic investigation revealed that berberine exerted profound inhibitory
effect on Id-1 expression. Knockdown of Id-1 inhibited the growth and
invasiveness of the HCC cells. Lastly, the anti-proliferative and anti-
invasive activities of berberine could be partially rescued by Id-1 over-
expression in HCCmodels. All these suggest a novel anti-cancer/anti-in-
vasive mechanism of berberine via Id-1 suppression.2. Materials and methods
2.1. Cell lines and berberine
Human HCC cell lines including MHCC-97L and MHCC-97L-
luciferase (from Liver Cancer Institute, Fudan University, Shanghai,
China [26]), HepG2 and SK-Hep1 (from American Type Culture Collec-
tion, Manassas, VA, USA) were maintained in DMEM with high glucose
(Life Technologies, Grand Island, NY) supplemented with 10% heat-
inactivated fetal bovine serum (Life Technologies), 100 U/ml penicillin
G, and 50 μg/ml streptomycin (Life Technologies) at 37 °C in a humidi-
ﬁed atmosphere containing 5% CO2. Cell lines were routinely authenti-
cated through cell morphology monitoring and identity veriﬁcation
using short tandem repeat proﬁling analysis. Berberine chloride waspurchased from Sigma and was dissolved in autoclaved H2O at 5 mM
as stock concentration.
2.2. Lungmetastasis model from orthotopic xenograft implant in nudemice
5 × 106 MHCC-97L-luciferase cells were subcutaneously inoculated
into the nude mice. Once the subcutaneous tumor reached 0.8 to 1 cm
in diameter, it was cut into approximately 1 mm3 pieces and
orthotopically implanted into the left lobes of the livers of another
groups of nude mice to allow for the development of lung metastases.
After 1week,micewith liver HCC tumor implantswere subjected to im-
aging analysis based on the luciferase signal. Brieﬂy,micewere anesthe-
tized with i.p. injection of sodium pentobarbital (50 mg/kg, Ceva Sante
Animale), and then injected with (100 mg/kg D-Luciferin, Caliper Life
Sciences) through subcutaneous injection into the back of the neck.
Mice showing successful implantation of the tumor were randomly di-
vided into control saline group (n = 7) and berberine treatment
group through i.p. injection (n = 7, 10 mg/kg/2 day). Liver tumor
growth was monitored weekly by Xenogen IVIS. The nude mice were
sacriﬁced after 35 days. For quantiﬁcation of lung metastasis, lungs
were excised for ex vivo imaging by Xenogen IVIS. All mice were fed in
standard condition with weight monitoring and sacriﬁced after 5-
week incubation. All the use of animals in this study was approved by
the Committee on the use of live animals in teaching and research, the
University of HongKong, HongKong. Volumeof the tumorwas calculat-
ed as follows: tumor volume (mm3) = (length × width2) / 2. To deter-
mine the lung metastases, 50 consecutive sections (4 μm)were cut and
subsequently stained with H&E. Themetastatic nodules were examined
by an experienced pathologist and a trained researcher.
The detailed protocols of in vivo tumorigenicity model, mitotic index
measure, immunostaining, MTT assay, wound healing assay, matrigel-
invasion assay and hypoxic treatment are described in Supplementary
Materials and Methods.
Immunoﬂuorescence staining, secretory VEGF protein quantiﬁca-
tion by ELISA, western blot analysis, Id-1 promoter assay, and protein
half-life estimation were used to assess protein/gene expression or
promoter activity in SK-Hep1, HepG2 and MHCC-97L. Detailed ex-
perimental procedures are described in Supplementary Materials
and Methods.
2.3. Statistical analysis
The data from each experiment were expressed asmean± standard
deviation (SD). Student's t test was used to assess the differences be-
tween experimental groups. A p value b 0.05 was considered as statisti-
cally signiﬁcant throughout this study.
3. Results
3.1. Berberine effectively inhibited growth of HCC xenografts in vivo
Recently, we reported that berberine could induce autophagic cell
death and mitochondria apoptosis in HCC cells in vitro [8]. The effects
of berberine as a therapeutic agent for HCC were further conﬁrmed
using in vivo animal system.We ﬁrst examined the in vivo inhibitory ef-
fects of berberine on the growth of MHCC-97L cells in nude mice. Five
millions of HCC (MHCC-97L) cells were injected subcutaneously into
nudemice (Fig. 1a–c). Berberine treatment (10 mg/kg/2 days) or saline
were administered into the mice by intraperitoneal (i.p.) injection
started on day 5 after tumor cell inoculation. As shown in Fig. 1c, the
in vivo growth rate of HCC cells in the berberine-treated group was sig-
niﬁcantly slower than the vehicle-treated group (*p b 0.05, **p b 0.005).
By day 35, the maximum tumor volume of the vehicle-treated group
reached 988.2 ± 158 mm3, while that of the berberine-treated group
was only 350.8 ± 110.3 mm3 (65 ± 16% growth inhibition by berber-
ine) (Fig. 1c). During the course of berberine treatment, the bodyweight
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Fig. 1. Berberine could suppress the tumor growth of HCC cells injected into nude mice subcutaneously. (a) A comparison of tumor volumes in mice treated with berberine (10 mg/kg/
2 day, i.p.) or saline (as control) after injectingMHCC-97L cells subcutaneously for 35 days. (b) The tumorswere excised from themice 35 days post-injection of the tumor cells. Thephotos
show that the tumors developed in berberine-treatedwere smaller than the ones developed in controlmice. (c) Graphical representation of the tumor volumeplotted fromday 5 to day 35
after subcutaneous injection of HCC cells. Signiﬁcant reduction in the size of tumorwas found in the berberine-treatedmice (n=5) than the saline-treated controlmice (n=5) (*p b 0.05,
**p b 0.005). (d) A comparable body weight of the nudemice with and without berberine treatment. Body weights were monitored throughout the course. (e) Berberine suppressed the
mitotic events in tumors. The tumor samples were collected on day 35 (n = 5) in each group, sectioned and stained with H & E. In the left panel, representative histological staining of a
tumor section from a control mouse is shown. The average number of mitotic index is presented in a bar-chart in the right panel. There was a signiﬁcant inhibition of mitotic events after
berberine treatmentswhen comparedwith the controls (**p b 0.005). (f) Berberine suppressed angiogenesis in the tumors. CD31 is amarker of endothelial cells. Tumorswere stainedwith
CD31 antibody for the evaluation of microvessel density. Representative photos are shown for the tissue sections obtained from mice in control and treatment groups (left panel).
Microvessel density was measured by counting the mean number of microvessel using 5 most vascularized areas under ×400 magniﬁcation (right panel) (*p b 0.05).
543C.M. Tsang et al. / Biochimica et Biophysica Acta 1852 (2015) 541–551andwell-being of themicewasmonitored carefully to assess any poten-
tial in vivo toxicity of berberine. As shown in Fig. 1d, the control and
berberine-treated mice had comparable body weight, suggesting that
therewas no severe toxicity in the berberine-treated group. Histologicalexamination of liver, kidney and lungs of the treated and control ani-
mals did not revealed signiﬁcant pathological changes (results not
shown). Histological examination of tumors harvestedupon completion
of treatment demonstrated that tumor from berberine-treated group
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ig. 2. Berberine could suppress the primary and metastatic growth of HCC cells in orthotopic mice model. (a) MHCC-97L cells tagged with luciferase reporter gene were orthotopically
planted into the left liver lobe of athymic nudemice. Luciferase signalwas followedwithin 5weeks by injecting luciferin into themice and visualized under Xenogen imager. Micewere
. administratedwith berberine (10mg/kg/2 days) or saline (as control). (b) Imaging of luciferase-expressing liver cancer cells that had been orthotopically implanted into nudemice for
5 days. Representative images taken from saline- and berberine-treated mice are shown. (c) After 5 weeks of orthotopic growth of HCC cells, the livers were excised. Photographs were
ken to illustrate the tumor growth (within yellow circle) in the upper panelwhile the tumor sizes are graphically shown in the lower panel (n=7 for both control and treatment group).
here was signiﬁcant reduction in the volume of tumor after berberine treatment (*p b 0.05). (d) Berberine suppressed the invasion of the orthotopic tumor cells into the livers. H & E
aining was done to reveal the histological features of tumors orthotropically developed in livers of mice with and without berberine treatment. Invasive growth front was found in
e control group. After berberine treatment, clear boundary between tumor and normal liver was observed. (e) The incident rate and the levels of lungmetastasis were lower in the ber-
erine-treatedmice than the control group. After the orthotopic implantation of tumors into the livers for 35days, the lungswere dissected out and bioluminescence signalswere captured
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gnals respectively among the lungswithmetastases. (f) Berberine suppressed the pulmonarymetastasis of theMHCC-97L cells. Lungmetastasis was inhibited by berberine treatment as
decrease in the intensity of luciferase signal was observed (in the upper panel). Ex vivo detection of the luciferase signals from the lungs are graphically shown in the lower panel (n= 7
r both control and treatment group). Signiﬁcant reduction in signal emitted from the lungs was observed in the berberine-treated group (**p b 0.005). (g) Consecutive sections of the
ngs excised from the control and berberine-treated mice were stained with H&E. In the upper panel, representative images taken at high and low power of magniﬁcation are shown to
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trol) (Fig. 1e, **p b 0.005), supporting an anti-proliferative action of ber-
berine on growth of HCC in vivo. Furthermore, we found that berberine
exerted potent anti-angiogenic effects in vivo as it effectively inhibited
the formation of new blood vessels (as indicated by CD31 staining for
micorovessel density) in xenografted tumor (Fig. 1f; ~80% lower in
the berberine-treated group compared to the vehicle-treated group;
*p b 0.05). Collectively, these results showed that berberine effectively
inhibited proliferation of HCC xenograft proliferation with suppression
of angiogenesis.
3.2. Berberine suppressed the primary and metastatic growth of
orthotopically implanted HCC in nude mice
Next, we investigated the anti-metastatic potential of berberine in
vivo. To best mimic the development of lung metastases from HCC, an
orthotopic HCC model which develops spontaneous lung metastases
(a most common site of metastases for liver cancer patients) was
used. Orthotopic implantation of MHCC-97L-luciferase (a metastatic
HCC cell line engineered to express luciferase) allowed live-animal im-
aging for the monitoring of the tumor growth in the liver by quantita-
tion of the bioluminescence emitted from the transplanted HCC
(Fig. 2a). The MHCC-97L-luciferase cells were ﬁrst grown as a subcuta-
neous tumor which was then cut into small pieces and implanted
orthotopically into the livers of nude mice. Successful transplantation
of viable tumor piece into individual mouse was conﬁrmed by xenogen
imaging one week after the surgery. Mice with comparable luciferase
signal intensitywere selected and randomized as control and treatment
groups. Fig. 2a shows the growth of the orthotopically implanted tumor
monitored longitudinally from week 1 to week 5 with or without
berberine treatment. In the berberine-treated mice, there was no re-
markable enhancement of the luciferase signal at 5 weeks after implan-
tation (Fig. 2a). This indicates that in the presence of berberine, the
growth rate of orthotopically implantedHCCwasnot prominent. In con-
trast, tumor implants in the vehicle-treated group animal continued to
grow into large tumors, giving out very strong luminescence signals.
Fig. 2b shows the growth of HCC xenograft in two representative mice
from each group after 5 weeks of berberine treatment. By measuring
the tumor size in the biopsied livers at the end of the experiments
(Fig. 2c), we conﬁrmed that there was around 80% inhibition of HCC
tumor growth in the berberine-treated mice compared to control mice.
Furthermore, we found that tumors in the control mice displayed ir-
regular and invasive edge at the growth front, illustrating signiﬁcant
local invasion of orthotopically implanted HCC cells into the normal
liver tissue (Fig. 2d). In contrast, the tumor growth front in the im-
planted livers in berberine-treated group showed regular and non-
invasive growth edge (Fig. 2d).
More strikingly, berberine treatment was found to be effective in
inhibiting the formation of distal pulmonary metastasis using this
orthotopic liver HCC tumor implant model. Fig. 2e summarizes the inci-
dence of distal lungmetastasis and also their levels of signal intensity in
the control and treated mice. Ex vivo imaging of luciferase signal was
employed at the end of the experiments as the lungs are located deeper
in the body of themice. This was to ensuremore accurate quantiﬁcation
of themetastasis signals. For the controlmice, 6 out of 7mice developed
lungmetastases,while only 4 out of 7 berberine-treatedmicedeveloped
metastases (Fig. 2e). More importantly, the overall luciferase signal in
the lungs, representing the extent of metastasized HCC cells, was
much stronger in the control mice than the berberine-treated mice
(Fig. 2e). Consistent with this, there was an inhibition of around 80% lu-
minescence signals in lungs in the treatedmice compared to the control
mice (Fig. 2f, **p b 0.005). The lung metastasis was conﬁrmed by histo-
pathological analysis. In agreement with the luminescence signals ob-
served, the number of metastatic foci in the lung and the size of the
lung metastases was greatly reduced in the berberine-treated group
vs. control group (Fig. 2g, *p b 0.05). Berberine, for the ﬁrst time, wasfound to harbor potent anti-metastatic activity against lung metastases
formation in HCC orthotopic model.3.3. Berberine inhibited invasive and angiogenic properties of HCC cells
To further support the notion that berberine could suppress thema-
lignant properties of HCC cells, the inhibitory effects of berberine on
multiple HCC cell lines (MHCC-97L, SK-Hep1 andHepG2)were evaluat-
ed. MTT assay was performed to determine the IC50 of berberine on
individual HCC cell line. Results showed that berberine inhibited prolif-
eration of all three out of three HCC lines examined in a dose- and time-
dependent manner (Fig. 3a). Prompted by the marked inhibition of de-
velopment of lungmetastasis formationbyberberine,we also examined
the effects of berberine on motility and invasive properties of HCC cells
in vitro. The effect of berberine onwound closure (as an indicator of cel-
lular migration) on HCC cells was examined. The results showed that
berberine (150 μM) could inhibit wound closure of HCC cells when
compared to vehicle control, indicating its inhibitory effect on mobility
and migration of HCC (Fig. 3b). Using matrigel invasion chamber
assay, berberine treatment also inhibited the HCC cells to invaded
through the matrigel-coated ﬁlter in the invasion chamber in a dose-
dependentmanner (Fig. 3c, *p b 0.05, **p b 0.005). These results suggest
that berberine could inhibit both the motility and invasiveness of HCC
cells.
Angiogenesis is an important factor contributing to cancer metasta-
tic events. The generation of new blood vessels facilitates nutrient sup-
ply and spreading of metastatic tumor. HIF-1α and VEGF are potent
angiogenic factors involved in cancer metastasis. Previous study had
showed that berberine could suppress HIF-1α expression in gastric ad-
enocarcinoma cells under hypoxia [7]. The effect of berberine on induc-
tion of HIF-1α in MHCC-97L was examined by Western blot analysis.
Under hypoxic condition (1% O2), the level of HIF-1α was upregulated
in MHCC-97L cells which could be effectively inhibited by berberine
(150 μM) (Fig. 3d). Our immuno-ﬂuorescence staining also conﬁrmed
the downregulation of HIF-1α in HCC cells (Fig. 3e). Since HIF-1α is
an upstream regulator of VEGF, it is likely that the observed inhibitory
effects of berberine onHIF-1α signalingmay lead to reduced production
of VEGF byHCC cells, resulting in the reduced formation of blood vessels
in berberine-treated HCC tumors observed in vivo (Fig. 1f). To test this
hypothesis, we examined the effects of berberine on VEGF production
by HCC cells. SK-Hep1 andMHCC-97L cells were subjected to normoxia
and hypoxic condition for 6, 16 and 24 h in the absence or presence of
berberine (150 μM) and the levels of secretory VEGF in the culture me-
dium were determined by ELISA (Fig. 3f). After 24 h incubation in
normoxic condition, the concentration of VEGF in SK-Hep1 cells was
around 2220 pg/ml. Treatment with berberine signiﬁcantly suppressed
VEGF production in SK-Hep1 cells (240 pg/ml), representing an 89% re-
duction of VEGF production (Fig. 3f). Hypoxia remarkable increased
VEGF secretion (from 2220 to 4920 pg/ml in 24 h). Berberine treatment
efﬁciently inhibited VEGF production from SK-Hep1 cells induced by
hypoxia by 83% (from 4920 pg/ml to 840 pg/ml) (Fig. 3f). Similar ﬁnd-
ings were observed in MHCC-97L cells. After 24 h incubation in
normoxic condition, the concentration of VEGFwas 5500 pg/ml, where-
as berberine inhibited around 50% of VEGF secretion (2720 pg/ml) in
MHCC-97L cells (Fig. 3f). The concentration of VEGF production in
MHCC-97L cells increased to 6890 pg/ml after 24 h incubation in hypox-
ic condition,while berberine suppressed theVEGF production to around
3900 pg/ml (Fig. 3f). We were able to demonstrate that berberine sup-
pressed the VEGF secretion in SK-Hep1 cells in a dose-dependent man-
ner (Fig. 3g). SK-Hep1 cells were subjected to various dosages of
berberine treatment (0, 32, 63, 125, 250 and 500 μM) under both
normoxia and hypoxic (1% O2) conditions for 16 h. At a relatively low
dosage (32 μM) of berberine, there was around 50% and 70% inhibition
of VEGF secretion in normoxic and hypoxic conditions respectively
(Fig. 3g).
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Thus far, we have showed that berberine could inhibit invasion, me-
tastasis and production of HIF-1α and VEGF in HCC cells (Figs. 2 and 3).
Recent studies have reported that Id-1 protein is overexpressed in HCC,
and is correlated with HCC development, portal vein invasion and
lymph node metastasis [16,27], indicating a crucial role of Id-1 in HCC
progression and metastasis. Therefore, we investigated if Id-1 may be0
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Normoxia Hypoxiainvolved in mediating the potent anti-invasive and anti-metastatic ac-
tivities of berberine in HCC which has never been examined. First, we
examined the effects of berberine on Id-1 expression in HCC cells. Sur-
prisingly, berberine was found to be very effective in suppressing Id-1
protein levels in all three HCC cell lines (MHCC-97L, HepG2 and SK-
Hep1) after 24 h treatment (Fig. 4a) A dose-dependent inhibition of
Id-1 level by berberine was observed (Fig. 4a). In both MHCC-97L and
HepG2 cells, low dose of berberine (62.5 μM) effectively suppressed
547C.M. Tsang et al. / Biochimica et Biophysica Acta 1852 (2015) 541–551the expression of Id-1 while higher doses of berberine resulted in com-
plete abrogation of Id-1 expression (Fig. 4a). Accompanying Id-1 inhibi-
tion, induction of cleaved PARP (as apoptotic marker) as well as
downregulation of cyclin D1 (as proliferative marker) were also ob-
served. We further examined the effects of berberine on transcription
activity of Id-1 promoter as well as half-life of Id-1 protein in berberine
treated cells. Results from Id-1 promoter luciferase reporter assays in
MHCC-97L cells demonstrated that berberine was capable of reducing
Id-1 promoter activity in a dose-dependent manner which has not
been previously reported (Fig. 4b, *p b 0.05, **p b 0.005). The half-life
of Id-1 protein in both vehicle- and CHX-treated cells were similar
after berberine treatment (Fig. 4c). These results suggest that the sup-
pressive effect of berberine on Id-1 expression was likely to be at the
transcription level.
Id-1 protein expressionwas also found to bedownregulated in the in
vivo HCC tumors of berberine-treated mice vs. that of the vehicle-
treated mice (Fig. 4d, **p b 0.005). Scorings of immunoreactivity were
based on the percentage of cells which were stained brown, Id-1 posi-
tive cells were quantiﬁed as 83 ± 12.3% in control mice and 25 ± 5.3%
in berberine-treated mice (Fig. 4d). Thus, berberine treatment was able
to inhibit Id-1 expression by around 70% in HCC tumors in vivo. Hence,
we have demonstrated the inhibitory effects of berberine in Id-1 expres-
sion in HCC cells under both in vivo and in vitro growth conditions.
3.5. Id-1 expression was critical for growth, invasion and VEGF production
in HCC cells
We further elucidated the role of Id-1 in HCC cancer growth and in-
vasion in HCC by knock-down study using shRNA.Western blot analysis
demonstrated the successful knockdown of Id-1 in MHCC-97L, HepG2
cells and SK-Hep1 (Fig. 5a). We then determined the proliferation rate
of the vector control and shId-1 transfected cell lines (Fig. 5b). Our re-
sults showed that knockdown of Id-1 could inhibit the growth of all
three HCC cell lines (Fig. 5b). Furthermore, the invasive properties of
HCC cells were signiﬁcantly reduced (~60%) in Id-1 knock-down HCC
cells compared to control cells (Fig. 5c, *p b 0.05, **p b 0.005). This re-
duction of HCC cell invasion was also accompanied by a reduced pro-
duction of VEGF from HCC cells. As shown in Fig. 5d, speciﬁc
knockdown of Id-1 abrogated VEGF secretion by both SK-Hep1 and
MHCC-97L cells (*p b 0.05, **p b 0.005). These results support an impor-
tant contribution of Id-1 expression to promote HCC cell proliferation,
invasion and VEGF secretion.
3.6. Overexpression of Id-1 rescued the inhibitory effects of berberine on
HCC proliferation and invasion in HCC
We have shown that berberine could exert anti-tumorigenic and
anti-invasive effects in HCC cells in both in vivo and in vitro models.
Id-1, being one of the oncogenic proteins, could be potently downregu-
lated by berberine through transcriptional modulation. Expression of
Id-1 was also much reduced in the tumors in mice. All these indicate
that Id-1 may be the mediator for the anti-cancer effects of berberine.Fig. 3. Berberine suppressed the growth, migration, invasion and pro-angiogenic activities of t
growth of liver cancer cells. The percentage of viable MHCC-97L, HepG2 and SK-Hep1 cells aft
by MTT assay. (b) Berberine inhibited the migration potential of HCC cells. Cells were seeded a
the cell mono-layers. They were then either left untreated or treated with berberine (150 μM
time points. (c) Berberine inhibited the invasive potential ofMHCC-97L andHepG2 cells. Cellsw
Photos were taken forMHCC-97L and HepG2 cancer cells which had invaded through thematri
panel, here is a table showing themean number of invaded cells± SD in three randomizedﬁeld
HIF-1α induced by hypoxic condition.Western blot was done to show the expression of HIF-1α
treatment (150 μM). (e) Berberine could suppress the expression of HIF-1 α under hypoxic co
expression was visualized using immuno-ﬂuorescence staining. (f) Suppression of VEGF secr
berberine (150 μM) and subjected to normoxic and hypoxic (1% O2) conditions for 6, 16 and 2
dependent effect of berberine in suppressing the release of VEGF from the HCC cells. SK-Hep1 ce
conditions. Secretion of VEGF was quantitated by ELISA.The inhibitory effects of berberine on this key oncoprotein, Id-1, has
not been previously reported. We sought to determine if this downreg-
ulation of Id-1 expression by berberine contributes to its potent anti-
proliferative and anti-invasive activity in HCC or not. We overexpressed
Id-1 into MHCC-97L cells (Fig. 6a) and indeed our results showed that
ectopic expression of Id-1 was able to partially rescue the HCC cells
from the growth inhibitory and anti-invasive activity of berberine (vs.
control) (Fig. 6b–c). Results from the proliferation assay showed that
Id-1 expression could rescue HCC growth by around 40% at day 4
(Fig. 6b). More importantly, Id-1 expression abrogated the anti-
invasive activity of berberine in HCC cells by around 60% (Fig. 6c). Over-
all, our results demonstrated for the ﬁrst time that Id-1 downregulation
was involved in the anti-proliferative and anti-invasive mechanism of
berberine in HCC cells.4. Discussion
HCC is known for its highly malignant and metastatic phenotype
[11–14]. Recurrence and metastasis remain as themajor causes of mor-
tality of HCC patients even after the tumors have been surgically re-
moved [12,14,15]. The high recurrence rate is due to the high
propensity of HCC for vascular invasion and metastasis [14]. On the
other hand, chemotherapy is commonly applied for inoperable HCC,
but its results are often discouraging because of chemoresistance con-
ferred by p53 mutation in HCC cells and toxicity of chemotherapeutic
agents to normal cells [28]. The potent anti-tumor effects of berberine
has been reported in multiple cancer types [2,6,8,9]. In agreement
with other published reports showing the anti-cancer effects of berber-
ine, we have also demonstrated the inhibitory effects of berberine on
the growth of HCC in vivo (Fig. 1). The anti-proliferative activity of ber-
berine onHCC observed in vivowas accompanied by anti-angiogenic ac-
tivity (Fig. 1). However, the detail cellular mechanisms of berberine on
HCC cells are not well understood. In this study, we reported for the
ﬁrst time the potent anti-metastatic activity of berberine in an
orthotopic model of HCC, which develops spontaneous lung metastasis
from HCC tumor implants in the liver. The metastasis potential of HCC
cells is rarely studied in vivo, partially due to the lack of in vivo model
to resemble the soil-and-seed environment for developing metastases.
Subcutaneous tumors in animal models can only provide limited infor-
mation for tumor metastasis. Using the orthotopic model, we could
monitor the suppressive effects of berberine on both the primary and
metastatic growth of HCC. Consistent with the observation of inhibitory
effects of berberine on subcutaneously transplanted HCC cells in animal,
we were also able to conﬁrm the suppressive effects of berberine on
growth of orthotopically transplanted HCC growth as indicated by live
animal imaging of tumor growth monitored by the luciferase signals
in HCC cells (Fig. 2a and b). At the end of 6 weeks treatment period,
the excised tumors in the berberine-treated group were at least 5-
folds smaller compared to control mice (Fig. 2c). In addition, the
orthotopically implanted HCCmodel also enabled us to examine the ef-
fects of berberine on the local and distal metastatic potentials of HCC
cells (Fig. 2d–g). Interestingly, the tumor implants in the vehicle-he HCC cells in vitro. (a) Time- and dose-dependent inhibitory effects of berberine on the
er treated with berberine ranging from 0 to 1000 μM at 24, 48 and 72 h was determined
nd allowed to reach 95% conﬂuency. Wound was created by scraping with pipette tip on
) for 0, 24, 48 and 72 h. Representative photo was shown for each treatment at different
ere plated in the chamber and allowed to invade for 24 h in 0, 125 and 250 μMof berberine.
gel layer. Representative photo for each treatment was shown in the left panel. In the right
s for each treatment (*p b 0.05, **p b 0.005). (d) Berberine could suppress the expression of
inMHCC-97L cells under normoxia and hypoxic conditionswith or without the berberine
ndition. Cells were subjected to hypoxia (1% O2) for 16 h and the upregulation of HIF-1α
etion by berberine in liver cancer cells. SK-Hep1 and MHCC-97L cells were treated with
4 h. Culture media were collected and secreted VEGF was quantiﬁed by ELISA. (g) Dose-
lls were treatedwith serial concentrations of berberine under both normoxic and hypoxic
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Fig. 4. Berberine suppressed the expression of Id-1 by inhibiting the promotor activity of Id-1. (a) Down-regulation of Id-1 and cyclin D1 by non-cytotoxic doses of berberine. MHCC-97L,
HepG2 and SK-Hep1were treatedwith serial concentrations of berberine for 24 h.Western blots were done to show the expression of Id-1, cyclin D1 (proliferative indicator) and cleaved-
PARP (apoptotic marker) in the upper panel. Equal amount of protein was analyzed and β-actin was used as loading control. Three independent experiments were performed and the
densitometry of the bands was quantitated by ImageJ. In the lower panel, the bar charts representing the relative expression levels of Id-1, cyclin D1 and cleaved-PARP are shown.
Each protein level was ﬁrst normalized with the expression of β-actin. The normalized expression of Id-1 and cyclin D1 at 0 μM of berberine treatment was assigned as 1 arbitrary
unit, while the normalized expression of cleaved-PARP at 1000 μM of berberine treatment was assigned as 1 arbitrary unit. On the other hand, cleaved-PARP level was upregulated at
high concentrations (range 125–1000 μM). (b) Berberine suppressed the promoter activity of Id-1 in a dose-dependent manner. Dual reporter luciferase assay was performed by
transfecting pGL-Id-1-luc and pRL-CMV-luc into theMHCC-97L cells under a serial concentrations of berberine (0, 50, 100 and 200 μM). The renilla luciferase activitywasused to normalize
the variation in transfection efﬁciency. (c) Berberine did not affect the protein stability of Id-1. The cells were treated with cycloheximide (CHX) so as to block protein synthesis. Proteins
were then collected at the indicated time points of the control and berberine-treated (100 μM) cells. Three independent experimentswere done and the representativewestern blots of Id-
1 and β-actin are shown in the upper panel. Densitometry of the bands was performed and the relative expression level of Id-1 in the control and berberine-treated cells is shown in the
lowerpanel. (d) Berberine suppressed the Id-1 expression inorthotropic tumors. Expression of Id- 1 in theorthotopic tumormodelswas detected by immunostaining. Strong expression of
Id-1 was shown in the tumor sections obtained from control mice, while weak expression of Id-1 was shown in the tumor sections obtained frommice under berberine treatment (left
panel). The bar chart on the right shows the percentage of cells with Id-1 expression in the tumor sections. Cells with Id-1 expression was counted in 3 randomized ﬁelds for each group
(n = 7, *p b 0.05, **p b 0.005).
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Fig. 5. Knockdown of Id-1 suppressed the growth, invasion and VEGF secretion of HCC cells. (a) Successful knockdown of Id-1 inHCC cell lines were shown inWestern blot analysis. Stable
knockdown of Id-1 was done by lenti-viral transfer of short hairpin (sh) construct of Id-1 into MHCC-97L, HepG2 and SK-Hep1 cells. (b) Knockdown of Id-1 suppressed the proliferation
ofHCC cells. 1 × 105 vector control or shId-1HCC cellswere seeded into eachwell of a 6-well plate. The growth curveswere drawn by counting the number of cells after seeding for 1, 2 and
4 days. (c) The invasiveness ofMHCC-97L cells were downregulated by suppressing the expression of Id-1. The number of invaded cells through thematrigel-coated chamber insert were
counted after allowing the control and shId-1 cells to invade for 24 and 48 h (*p b 0.05, **p b 0.005). (d) Knockdown of Id-1 downregulated the secretion of VEGF fromMHCC-97L and SK-
Hep1 cells. ELISA was used to quantitate the concentration of VEGF released from both the control and Id-1 knockdown cells (*p b 0.05, **p b 0.005).
549C.M. Tsang et al. / Biochimica et Biophysica Acta 1852 (2015) 541–551treated group showed very extensive irregular invasive fronts, which
was suggestive of extra-tumoral invasion. However, after berberine
treatment, a smoothmargin between tumor front and the adjacent nor-
mal liver tissuewas observed, whichwas indicative of less invasive phe-
notype of HCC cells (Fig. 2d). The orthotopic implantation model
effectively mimick the natural environment for the liver tumor to
grow and develop metastasis. Our results indicated that berberine
could suppress local invasion of the primary tumor to compromisemet-
astatic properties of HCC cells. The MHCC-97L cell line is a metastatic
HCC cell line known to develop distal metastases preferentially in lung
[26]. Based on the bioluminescence imaging from the lungs of the
mice, we observed a much more intense luciferase signal from control
untreated mice compared to berberine-treated mice indicating
suppression of lung metastasis from the orthotopically implanted HCC
cells by berberine (Fig. 2e). The suppression of micro-pulmonary
metastasis could be conﬁrmed by performing histopathological exami-
nation of consecutive sections of the lungs in control and treated ani-
mals (Fig. 2f). Our results demonstrated for the ﬁrst time the anti-
metastatic activity of berberine on HCC cells in vivo.
The suppressive effect of berberine on cell proliferation, angiogene-
sis and invasion could also be observed in several in vitro systems
(Fig. 3a–c). The anti-invasive and anti-metastatic effects of the berber-
ine could be reﬂected by its ability to suppress the cell from migrating
and then invading the cellular matrix. The anti-angiogenic effect of ber-
berinewas also evident by the inhibition of HIF-1α/VEGF pathway. HIF-
1αwas shown to be suppressed by berberine in bothWestern blot anal-
ysis and immuno-ﬂuorescence staining (Fig. 3d–e). This is in line with a
previous study showing that berberine could facilitate degradation ofHIF-1α by promoting acetylation at the Lys532 [7]. In addition, berber-
ine was shown to inhibit VEGF secretion in SK-Hep1 and MHCC-97L
cells upon exposure to hypoxia in both time- and dose-dependentman-
ner (Fig. 3f–g). Our study demonstrated that the administration of
berberine could elicit potent anti-angiogenic effects, potentially via
inhibition of the HIF-1α/ VEGF axis. Clinically, anti-VEGF treatment is
one of the strategies to control HCC progression [29,30]. VEGF targeting
leads to pruning of the tumor vasculature, reduction in vessel tortuosity,
and a drop in interstitial ﬂuid pressure, a process termed vessel normal-
ization [31]. Furthermore, it was reported that combination of a
cytotoxic drug with anti-VEGF agent leads to a rapid decrease in inter-
stitial ﬂuid pressure, whichmay enhance the delivery of chemotherapy
to tumor cells [32]. This suggests that berberinemay be an alternative or
adjuvant agent that can suppress angiogenesis in HCC tumors.
Here, we also reported for the ﬁrst time that Id-1 transcription
could be efﬁciently downregulated by berberine (Fig. 4). Overex-
pression of Id-1 is a key factor involved in cancer progression and
correlated with cancer aggressiveness [22–24]. It has been reported
that Id-1 overexpression induced HCC cell proliferation through
inactivation of p16INK4a/ retinoblastoma (RB) pathway [33]. We
have also previously reported that overexpression of Id-1 correlates
with HCCmetastasis, and ectopic expression of Id-1 promotes angio-
genesis and invasion through induction of VEGF secretion [16,18,23].
By knocking down Id-1 in the HCC cell lines, we showed that Id-1 ex-
pression was essential to support HCC tumor growth, angiogenesis
and invasion (Fig. 5). Moreover, overexpression of Id-1 in HCC cells
reversed the effects of berberine on inhibition of proliferation and in-
vasion (Fig. 6). All these results support a novel action of berberine
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Fig. 6.Overexpression of Id-1 rescued the anti-growth and anti-invasive effects of berberine. (a)Western blot analysis conﬁrmed the overexpression of Id-1 inMHCC-97L cells. Exogenous
expression of Id-1 was done by retro-viral transduction of Id-1 gene into the cells. (b) Overexpression of Id-1 rescued the growth-inhibitory effect of berberine. The vector control or Id-1
overexpressing HCC cells were either untreated or treatedwith berberine (100 μM) for 1, 2 and 4 days. The proliferative potential of the cells were determined by counting the number of
viable cells at the indicated time points. (c) Overexpression of Id-1 suppressed the anti-invasive effect of berberine. The vector control or Id-1 overexpressing HCC cells were plated in the
invasion chambers and allowed to invade through the matrigel coated membrane for 48 h. Under the treatment of berberine (100 μM), the Id-1 overexpressing cells could invade better
than the vector control cells (**p b 0.005).
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berberine.
Previous studies have suggested that Id-1 is potentially a highly
selective and effective target for cancer therapy [18,23]. Given the
fact that Id-1 overexpression is found in many different types of
human cancers, it is likely that berberine may also have anti-
invasive/anti-metastatic activity against other cancers, in addition
to HCC. In conclusion, berberine may represent a promising therapy
for HCC, potentially in the prevention of lung metastases and HCC
tumor growth.Novelty and impact statements
The growth and metastasis of HCC could be potently suppressed by
berberine in both subcutaneous and orthotopic mice models. Berberine
signiﬁcantly reduced the incident rate and size of lung metastasis from
the liver tumors. Further examination revealed that berberine effective-
ly downregulated the expression of Id-1 at the transcriptional level by
inhibiting the Id-1 promoter. Our results support a novel action of ber-
berine on Id-1 to mediate the anti-proliferative and anti-metastatic ac-
tivity of berberine.Disclosure of potential conﬂicts of interest
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